12 Results for "

EBC-1 cells

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "EBC-1 cells" in MCE Product Catalog:

Cat. No.: HY-175321
Research Areas:  

Inflammation/Immunology Cancer

PROTAC c-Met degrader-6 is a potent and orally active c-Met PROTACdegrader. PROTAC c-Met degrader-6 significantly induces the degradation of the c-Met protein with DC50s of 0.52 nM and 0.45 nM in EBC-1 and Hs746T. PROTAC c-Met degrader-6 almost abrogates the migratory and invasion abilities of tumor cells and significantly induces the apoptosis and blocks the cell cycle in the G0/G1 phase. PROTAC c-Met degrader-6 can be used for the study of various cancers such as non-small cell lung cancer and stomach cancer .
loading...
    loading...
Cat. No.: HY-175320
Research Areas:  

Cancer

PROTAC c-Met degrader-5 (Compound D19) is an orally active c-Met PROTAC degrader with DC50s of 0.42 and 0.32 nM in EBC-1 and Hs746T cells, respectively. PROTAC c-Met degrader-5 significantly induces cell apoptosis, G1 cell cycle arrest, and inhibits cell migration and invasion. PROTAC c-Met degrader-5 has potent antiproliferative and degradation efficacy against c-Met-addicted cancer cells and Tepotinib (HY-14721)-resistant cancer cells . Pink: c-Met ligand (HY-W425461); Blue: CRBN ligase ligand (HY-14658); Black: linker
loading...
    loading...
Cat. No.: HY-P991660

Target:  

c-Met/HGFR

Research Areas:  

Cancer

ARGX-111 is an anti-MET antibody. ARGX-111 blocks HGF-dependent and -independent signaling, downregulating MET expression on the tumor cell surface. ARGX-111 depletes MET-expressing circulating tumor cells through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby inhibiting tumor metastasis. ARGX-111 depletes circulating tumor cells and inhibits bone and lung metastasis in an orthotopic mouse model of metastatic breast cancer. ARGX-111 is promising for research in breast cancer and other cancers .
loading...
    loading...
Cat. No.: HY-149511
CAS No.: 3125694-57-4
Target:  

c-Met/HGFR Apoptosis PDGFR

Research Areas:  

Cancer

MET/PDGFRA-IN-2 (compound 8h) is a MET and PDGFRA protein inhibitor. MET/PDGFRA-IN-2 induces cell apoptosis. MET/PDGFRA-IN-2 inhibits proliferation of MET-positive cells (IC50s: 9.7, 6.1, 12.0, 11.5, 8.6, 34.4 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) .
loading...
    loading...
Cat. No.: HY-149510
CAS No.: 3125694-48-3
Target:  

c-Met/HGFR Apoptosis PDGFR

Research Areas:  

Cancer

MET/PDGFRA-IN-1 (compound 8c) is a MET and PDGFRA protein inhibitor (IC50: 36 μM for MET). MET/PDGFRA-IN-1 inhibits MET phosphorylation and induces cell apoptosis. MET/PDGFRA-IN-1 inhibits proliferation of MET-positive cells (IC50s: 15.3, 19.0, 22.0, 25.6, 21.0, 31.5 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) .
loading...
    loading...
Cat. No.: HY-173124
Target:  

CDK VEGFR PDGFR Apoptosis

Research Areas:  

Cancer

CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells .
loading...
    loading...
Cat. No.: HY-147575
CAS No.: 2231424-62-5
Target:  

TAM Receptor c-Met/HGFR

Research Areas:  

Cancer

Axl-IN-8 (NO.1) is a potent AXL inhibitor, with an IC50 of <1 nM. Axl-IN-8 also inhibits c-MET, with an IC50 of 1-10 nM. Axl-IN-8 shows anti-proliferative activity against BaF3/TEL-AXL, MKN45, and EBC-1 cells, with IC50 values of <10, 226.6 and 120.3 nM, respectively .
loading...
    loading...
Cat. No.: HY-173227
CAS No.: 1877313-32-0
Target:  

Trk Receptor

Research Areas:  

Cancer

TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC. The IC50 values for EBC-1 and HT-29 cells are 3.3-7.1 and 7.3-10.2 μΜ, respectively. TrkC-IN-1 is expected to be used in the research of the anti-cancer field .
loading...
    loading...
Cat. No.: HY-168910
Research Areas:  

Cancer

PROTAC c-Met degrader-3 is a c-Met PROTAC degrader with a DC50 of 0.59 nM. PROTAC c-Met degrader-3 induces ubiquitination and degradation of c-Met. PROTAC c-Met degrader-3 induces Apoptosis. PROTAC c-Met degrader-3 can be used in lung cancer-related research .
loading...
    loading...
Cat. No.: HY-157519
CAS No.: 3018150-68-7
Target:  

Apoptosis c-Met/HGFR

Research Areas:  

Cancer

LAH-1 is a c-Met inhibitor with oral activity and membrane permeability with an IC50 of 49 nM. LAH-1 has anticancer activity and can induce apoptosis, migration, and invasion .
loading...
    loading...
Cat. No.: HY-P992146
CAS No.: 3060218-90-5
Synonyms: MYTX-011 Antibody; Q-397

Research Areas:  

Cancer

Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-183749
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

c-Met-IN-29 is an orally active c-Met inhibitor with an IC50 of 1.6 nM. c-Met-IN-29 binds to and functionally modulates c-Met protein, inhibiting tumor cell proliferation, migration and apoptosis. c-Met-IN-29 exhibits anti-tumor activity both in vitro and in vivo. c-Met-IN-29 can be used for the research of non-small cell lung cancer .
loading...
    loading...
  • 1